All In Biotech

NDA 208462 · Takeda Pharms USA

Ninlaro

Ixazomib Citrate · Oral

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Jul 1, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Nov 20, 2015

Approved uses

2

Original approval plus efficacy supplements

Registered trials

155

13 Phase 3, 5 recruiting

FAERS reports

28,726

21,353 serious, 5,294 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 11, 2026.

NINLARO ® is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. NINLARO is a proteasome inhibitor indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. ( 1 ) Limitations of Use : NINLARO is not recommended for use in the maintenance setting or in newly diagnosed multiple myeloma in combination with lenalidomide and dexamethasone outside of controlled clinical trials. ( 1 ) Limitations of Use : NINLARO is not recommended for use in the maintenance setting or in newly diagnosed multiple myeloma in combination with lenalidomide and dexamethasone outside of controlled clinical trials [see Warnings and Precautions (5.9) and Clinical Studies (14.2 , 14.3) ] .

Mechanism: Ixazomib is a reversible proteasome inhibitor. Ixazomib preferentially binds and inhibits the chymotrypsin-like activity of the beta 5 subunit of the 20S proteasome. Ixazomib induced apoptosis of multiple myeloma cell lines in vitro. Ixazomib demonstrated in vitro cytotoxicity against myeloma cells from patients who had relapsed after multiple prior therapies, including bortezomib, lenalidomide, and dexamethasone. The combination of ixazomib and lenalidomide demonstrated synergistic cytotoxic effects in multiple myeloma cell lines. In vivo, ixazomib demonstrated antitumor activity in a mouse...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 28, 2022 Supplement 12 · Efficacy OrphanLabel
  • Nov 20, 2015 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelReviewSummary Review
3 products under this application
  • NINLARO · IXAZOMIB CITRATE EQ 2.3MG BASE · CAPSULE, ORAL · Prescription
  • NINLARO · IXAZOMIB CITRATE EQ 3MG BASE · CAPSULE, ORAL · Prescription
  • NINLARO · IXAZOMIB CITRATE EQ 4MG BASE · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ixazomib" as an intervention, any sponsor and status, largest first.

All 155 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • plasma cell myeloma3,689
  • death3,317
  • diarrhoea3,163
  • off label use2,976
  • pneumonia1,937
  • fatigue1,921
  • nausea1,847
  • neuropathy peripheral1,454
  • vomiting1,110
  • rash1,089
  • thrombocytopenia1,050
  • platelet count decreased1,008

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20131
20143
201563
20161,879
20172,393
20183,382
20194,438
20204,066
20214,533
20222,966
20231,976
20241,630
20251,042
2026354

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Ninlaro (Ixazomib Citrate)

2024 spending

$273M

Beneficiaries

2,983

21,413 claims

Per beneficiary

$91,419

$4,263.28 per unit

View as table
YearSpending
2020$378,740,491
2021$366,333,436
2022$340,652,030
2023$311,982,549
2024$272,703,342

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 120 on PubMed

Sponsor: Takeda

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.